Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NurExone Biologic Inc. (NRXBF : OTC)

• Company Description    NurExone Biologic Inc. is a pharmaceutical company which involved in developing a platform for biologically guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company's principal product includes ExoPTEN. NurExone Biologic Inc. is based in HAIFA, Israel. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.50 Daily Weekly Monthly 20 Day Moving Average: 5,544 shares Shares Outstanding: 83.15 (millions) Market Capitalization: $41.33 (millions) Beta: -0.51 52 Week High: $0.80 52 Week Low: $0.38 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.30% -30.18% 12 Week -8.12% -11.93% Year To Date 15.58% 1.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1 First Canadian Place Suite 1600 100 King Street West - Toronto,A6 M5X 1G5 CAN ph: - fax: - None https://nurexone.com

• General Corporate Information    Officers Lior Shaltiel - Chief Executive Officer and Director Yoram Drucker - Chairman Eran Ovadya - Chief Financial Officer Gadi Riesenfeld - Director Oded Orgil - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 67059R109 SIC: - Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/26/25 Share - Related Items Shares Outstanding: 83.15 Most Recent Split Date: (:1) Beta: -0.51 Market Capitalization: $41.33 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.08 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/26/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 25.96 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -454.66 03/31/25 - -375.11 ROA 09/30/25 - - 06/30/25 - -309.86 03/31/25 - -280.18 Current Ratio 09/30/25 - - 06/30/25 - 1.94 03/31/25 - 2.47 Quick Ratio 09/30/25 - - 06/30/25 - 1.94 03/31/25 - 2.47 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 0.02 03/31/25 - 0.02 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©